Anxiolytics

Β·
Β· BirkhΓ€user
αžŸαŸ€αžœαž—αŸ…β€‹αž’αŸαž‘αž·αž…αžαŸ’αžšαžΌαž“αž·αž…
181
αž‘αŸ†αž–αŸαžš
αž€αžΆαžšαžœαžΆαž™αžαž˜αŸ’αž›αŸƒ αž“αž·αž„αž˜αžαž·αžœαžΆαž™αžαž˜αŸ’αž›αŸƒαž˜αž·αž“αžαŸ’αžšαžΌαžœαž”αžΆαž“αž•αŸ’αž‘αŸ€αž„αž•αŸ’αž‘αžΆαžαŸ‹αž‘αŸ αžŸαŸ’αžœαŸ‚αž„αž™αž›αŸ‹αž”αž“αŸ’αžαŸ‚αž˜

αž’αŸ†αž–αžΈαžŸαŸ€αžœαž—αŸ…β€‹αž’αŸαž‘αž·αž…αžαŸ’αžšαžΌαž“αž·αž€αž“αŸαŸ‡

For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have even screened candidates as potential anxiolytics on their benzodiazepine-like side-effects rather than their anxiolytic activity. With the realisation of the drawbacks of the benzodiazepines, namely their potential for tolerance and dependency, there has been a renewed interest in alternative anxiolytics both from existing drugs such as the tricyclic and monoamine oxidase antidepressants and from newer agents such as buspirone. In addition anxiety is no longer considered to be a unique entity but rather an umbrella term for a series of specific anxiety disorders such as panic disorder without or with agoraphobia, generalised anxiety disorder (GAD), specific phobias, social phobias and post-traumatic stress disorder (PTSD). These new clinical categories have opened another dimension in the therapy of anxiety requiring the optimisation of treatments for different syndromes. This book is a critical review of today's anxiolytics and those that may become the anxiolytics of tomorrow. What is clear is that currently there are few clinically satisfactory alternatives to the benzodiazepines for the treatment of acute anxiety. For chronic anxiety, it is generally agreed that benzodi azepines are not the treatment of first choice. The tricyclic and monoamine oxidase antidepressants, the serotonin reuptake inhibitors and buspirone offer better solutions for chronic anxiety but they are still far from being ideal.

αžœαžΆαž™αžαž˜αŸ’αž›αŸƒαžŸαŸ€αžœαž—αŸ…β€‹αž’αŸαž‘αž·αž…αžαŸ’αžšαžΌαž“αž·αž€αž“αŸαŸ‡

αž”αŸ’αžšαžΆαž”αŸ‹αž™αžΎαž„αž’αŸ†αž–αžΈαž€αžΆαžšαž™αž›αŸ‹αžƒαžΎαž‰αžšαž”αžŸαŸ‹αž’αŸ’αž“αž€αŸ”

αž’αžΆαž“β€‹αž–αŸαžαŸŒαž˜αžΆαž“

αž‘αžΌαžšαžŸαž–αŸ’αž‘αž†αŸ’αž›αžΆαžαžœαŸƒ αž“αž·αž„β€‹αžαŸαž”αŸ’αž›αŸαž
αžŠαŸ†αž‘αžΎαž„αž€αž˜αŸ’αž˜αžœαž·αž’αžΈ Google Play Books αžŸαž˜αŸ’αžšαžΆαž”αŸ‹ Android αž“αž·αž„ iPad/iPhone αŸ” αžœαžΆβ€‹αž’αŸ’αžœαžΎαžŸαž˜αž€αžΆαž›αž€αž˜αŸ’αž˜β€‹αžŠαŸ„αž™αžŸαŸ’αžœαŸαž™αž”αŸ’αžšαžœαžαŸ’αžαž·αž‡αžΆαž˜αž½αž™β€‹αž‚αžŽαž“αžΈβ€‹αžšαž”αžŸαŸ‹αž’αŸ’αž“αž€β€‹ αž“αž·αž„β€‹αž’αž“αž»αž‰αŸ’αž‰αžΆαžαž±αŸ’αž™β€‹αž’αŸ’αž“αž€αž’αžΆαž“αž–αŸαž›β€‹αž˜αžΆαž“αž’αŸŠαžΈαž“αž’αžΊαžŽαž·αž αž¬αž‚αŸ’αž˜αžΆαž“β€‹αž’αŸŠαžΈαž“αž’αžΊαžŽαž·αžβ€‹αž“αŸ…αž‚αŸ’αžšαž”αŸ‹αž‘αžΈαž€αž“αŸ’αž›αŸ‚αž„αŸ”
αž€αž»αŸ†αž–αŸ’αž™αžΌαž‘αŸαžšβ€‹αž™αž½αžšαžŠαŸƒ αž“αž·αž„αž€αž»αŸ†αž–αŸ’αž™αžΌαž‘αŸαžš
αž’αŸ’αž“αž€αž’αžΆαž…αžŸαŸ’αžŠαžΆαž”αŸ‹αžŸαŸ€αžœαž—αŸ…αž‡αžΆαžŸαŸ†αž‘αŸαž„αžŠαŸ‚αž›αž”αžΆαž“αž‘αž·αž‰αž“αŸ…αž€αŸ’αž“αž»αž„ Google Play αžŠαŸ„αž™αž”αŸ’αžšαžΎαž€αž˜αŸ’αž˜αžœαž·αž’αžΈαžšαž»αž€αžšαž€αžαžΆαž˜αž’αŸŠαžΈαž“αž’αžΊαžŽαž·αžαž€αŸ’αž“αž»αž„αž€αž»αŸ†αž–αŸ’αž™αžΌαž‘αŸαžšαžšαž”αžŸαŸ‹αž’αŸ’αž“αž€αŸ”
eReaders αž“αž·αž„β€‹αž§αž”αž€αžšαžŽαŸβ€‹αž•αŸ’αžŸαŸαž„β€‹αž‘αŸ€αž
αžŠαžΎαž˜αŸ’αž”αžΈαž’αžΆαž“αž“αŸ…αž›αžΎβ€‹αž§αž”αž€αžšαžŽαŸ e-ink αžŠαžΌαž…αž‡αžΆβ€‹αž§αž”αž€αžšαžŽαŸαž’αžΆαž“β€‹αžŸαŸ€αžœαž—αŸ…αž’αŸαž‘αž·αž…αžαŸ’αžšαžΌαž“αž·αž€ Kobo αž’αŸ’αž“αž€αž“αžΉαž„αžαŸ’αžšαžΌαžœβ€‹αž‘αžΆαž‰αž™αž€β€‹αž―αž€αžŸαžΆαžš αž αžΎαž™β€‹αž•αŸ’αž‘αŸαžšαžœαžΆαž‘αŸ…β€‹αž§αž”αž€αžšαžŽαŸβ€‹αžšαž”αžŸαŸ‹αž’αŸ’αž“αž€αŸ” αžŸαžΌαž˜αž’αž“αž»αžœαžαŸ’αžαžαžΆαž˜β€‹αž€αžΆαžšαžŽαŸ‚αž“αžΆαŸ†αž›αž˜αŸ’αž’αž·αžαžšαž”αžŸαŸ‹αž˜αž‡αŸ’αžˆαž˜αžŽαŸ’αžŒαž›αž‡αŸ†αž“αž½αž™ αžŠαžΎαž˜αŸ’αž”αžΈαž•αŸ’αž‘αŸαžšαž―αž€αžŸαžΆαžšβ€‹αž‘αŸ…αž§αž”αž€αžšαžŽαŸαž’αžΆαž“αžŸαŸ€αžœαž—αŸ…β€‹αž’αŸαž‘αž·αž…αžαŸ’αžšαžΌαž“αž·αž€αžŠαŸ‚αž›αžŸαŸ’αž‚αžΆαž›αŸ‹αŸ”